Avapritinib Maintenance for AML With KIT Mutations
ConditionAML, Adult
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age14-70
SponsorRuijin Hospital
About this trial
A multicenter, single-arm clinical study of evaluate the efficacy and safety of avapritinib as maintenance therapy following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with KIT mutation.
Eligibility criteria
Qualifiers
Age≥ 14 years old;
First allo-HSCT for AML (including secondary AML) ;
KIT mutation at diagnosis (no restriction on locus for kit mutation
CR and negative MFC-MRD prior to initiation of maintenance therapy;
Disqualifiers
concurrently receiving other targeted therapies for AML;
Prior treatment with a TKI inhibitor that proved ineffective;
with concurrent FLT3-ITD mutations at enrollment;
Acute/chronic graft-versus-host disease requiring systemic immunosuppressive therapy prior to maintenance therapy;
Trial design
Treatments tested in this trial
- Avapritinib
Treatment groups
47 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov